Lombard Odier Asset Management Switzerland SA Makes New Investment in Waters Corporation $WAT

Lombard Odier Asset Management Switzerland SA bought a new stake in Waters Corporation (NYSE:WAT) in the first quarter, HoldingsChannel reports. The institutional investor bought 2,407 shares of the medical instruments supplier’s stock, valued at approximately $717,000.

Several other institutional investors also recently made changes to their positions in the stock. Anchor Investment Management LLC purchased a new position in shares of Waters in the 1st quarter valued at about $27,000. Zions Bancorporation National Association UT boosted its holdings in Waters by 121.2% during the fourth quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 40 shares in the last quarter. Vision Retirement LLC purchased a new stake in Waters during the first quarter worth about $29,000. Bollard Group LLC acquired a new position in Waters during the first quarter worth about $29,000. Finally, Louisbourg Investments Inc. acquired a new position in Waters during the first quarter worth about $30,000. 94.01% of the stock is currently owned by hedge funds and other institutional investors.

Waters Stock Performance

Shares of WAT opened at $384.67 on Wednesday. Waters Corporation has a 12-month low of $275.05 and a 12-month high of $414.15. The stock has a market cap of $37.77 billion, a P/E ratio of 48.88, a PEG ratio of 2.24 and a beta of 1.20. The company has a current ratio of 1.79, a quick ratio of 1.13 and a debt-to-equity ratio of 0.32. The company has a 50-day moving average of $367.04 and a two-hundred day moving average of $345.48.

Waters (NYSE:WAT) last released its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 EPS for the quarter, beating the consensus estimate of $2.31 by $0.39. Waters had a net margin of 11.91% and a return on equity of 15.60%. The business had revenue of $1.27 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same period in the prior year, the business earned $2.25 earnings per share. The company’s quarterly revenue was up 91.4% on a year-over-year basis. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. As a group, research analysts predict that Waters Corporation will post 14.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

WAT has been the subject of a number of research reports. Barclays lifted their price target on shares of Waters from $400.00 to $425.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Bank of America raised their price objective on Waters from $370.00 to $400.00 and gave the company a “neutral” rating in a research note on Tuesday, June 2nd. Royal Bank Of Canada began coverage on Waters in a report on Wednesday, July 8th. They set an “outperform” rating and a $435.00 price objective for the company. Evercore reiterated an “outperform” rating and set a $410.00 target price on shares of Waters in a research report on Monday, July 6th. Finally, The Goldman Sachs Group upped their target price on Waters from $380.00 to $425.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $401.60.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.